HIV treatment eligibility expansion and timely antiretroviral treatment initiation following enrollment in HIV care: A metaregression analysis of programmatic data from 22 countries

1. Eholie SP, Vella S, Anglaret X. Commentary: Antiretroviral therapy initiation criteria in low resource settings—from ‘when to start’ to ‘when not to start’. AIDS. 2014;28 Suppl 2:S101–4. doi: 10.1097/QAD.0000000000000237 24849468

2. Bock NN, Emerson RC, Reed JB, Nkambule R, Donnell DJ, Bicego GT, et al. Changing Antiretroviral Eligibility Criteria: Impact on the Number and Proportion of Adults Requiring Treatment in Swaziland. J Acquir Immune Defic Syndr. 2016;71(3):338–44. doi: 10.1097/QAI.0000000000000846 26361174

3. Siegfried N, Uthman OA, Rutherford GW. Optimal time for initiation of antiretroviral therapy in asymptomatic, HIV-infected, treatment-naive adults. Cochrane Database Syst Rev. 2010;(3):Cd008272. doi: 10.1002/14651858.CD008272.pub2 20238364

4. The TEMPRANO ANRS Study Group. A Trial of Early Antiretrovirals and Isoniazid Preventive Therapy in Africa. N Engl J Med. 2015;373(9):808–22. doi: 10.1056/NEJMoa1507198 26193126.

5. Lundgren JD, Babiker AG, Gordin F, Emery S, Grund B, Sharma S, et al. Initiation of Antiretroviral Therapy in Early Asymptomatic HIV Infection. N Engl J Med. 2015;373(9):795–807. doi: 10.1056/NEJMoa1506816 26192873

6. Ray M, Logan R, Sterne JA, Hernandez-Diaz S, Robins JM, Sabin C, et al. The effect of combined antiretroviral therapy on the overall mortality of HIV-infected individuals. AIDS. 2010;24(1):123–37. doi: 10.1097/QAD.0b013e3283324283 19770621

7. Montaner JS, Hogg R, Wood E, Kerr T, Tyndall M, Levy AR, et al. The case for expanding access to highly active antiretroviral therapy to curb the growth of the HIV epidemic. Lancet. 2006;368(9534):531–6. doi: 10.1016/S0140-6736(06)69162-9 16890841

8. Loutfy MR, Wu W, Letchumanan M, Bondy L, Antoniou T, Margolese S, et al. Systematic review of HIV transmission between heterosexual serodiscordant couples where the HIV-positive partner is fully suppressed on antiretroviral therapy. PLoS ONE. 2013;8(2):e55747. doi: 10.1371/journal.pone.0055747 23418455. Erratum in: PLoS ONE. 2013;8(12)

9. Attia S, Egger M, Muller M, Zwahlen M, Low N. Sexual transmission of HIV according to viral load and antiretroviral therapy: systematic review and meta-analysis. AIDS. 2009;23(11):1397–404. doi: 10.1097/QAD.0b013e32832b7dca 19381076

10. Levi J, Raymond A, Pozniak A, Vernazza P, Kohler P, Hill A. Can the UNAIDS 90-90-90 target be achieved? A systematic analysis of national HIV treatment cascades. BMJ Glob Health. 2016; Sep 15;1(2):e000010. doi: 10.1136/bmjgh-2015-000010 28588933

11. Cohen MS, Chen YQ, McCauley M, Gamble T, Hosseinipour MC, Kumarasamy N. Prevention of HIV-1 infection with early antiretroviral therapy. N Engl J Med. 2011;365. doi: 10.1056/NEJMoa1105243 21767103

12. Eholié SP, Badje A, Kouame GM, N’takpe J-B, Moh R, Danel C, et al. Antiretroviral treatment regardless of CD4 count: the universal answer to a contextual question. AIDS Res Ther. 2016;13(1):27. doi: 10.1186/s12981-016-0111-1 27462361

13. Jain V, Byonanebye DM, Amanyire G, Kwarisiima D, Black D, Kabami J, et al. Successful Antiretroviral Therapy Delivery and Retention in Care Among Asymptomatic Individuals with High CD4+ T Cell Counts ≥350 cells/uL in Rural Uganda. AIDS. 2014;28(15):2241–9. doi: 10.1097/QAD.0000000000000401 25022596

14. Hall HI, Tang T, Westfall AO, Mugavero MJ. HIV care visits and time to viral suppression, 19 U.S. jurisdictions, and implications for treatment, prevention and the national HIV/AIDS strategy. PLoS ONE. 2013;8(12):e84318. doi: 10.1371/journal.pone.0084318 24391937

15. Clouse K, Pettifor A, Maskew M, Bassett J, Van Rie A, Gay C, et al. Initiating antiretroviral therapy when presenting with higher CD4 cell counts results in reduced loss to follow-up in a resource-limited setting. AIDS. 2013;27(4):645–50. doi: 10.1097/QAD.0b013e32835c12f9 23169326

16. World Health Organization. Guideline on when to start antiretroviral therapy and on pre-exposure prophylaxis for HIV. Geneva: World Health Organization; 2015.

17. Rosen S, Fox MP. Retention in HIV care between testing and treatment in sub-Saharan Africa: a systematic review. PLoS Med. 2011;8(7):e1001056. doi: 10.1371/journal.pmed.1001056 21811403

18. Mugglin C, Estill J, Wandeler G, Bender N, Egger M, Gsponer T, et al. Loss to programme between HIV diagnosis and initiation of antiretroviral therapy in sub-Saharan Africa: systematic review and meta-analysis. Trop Med Int Health. 2012;17(12):1509–20. doi: 10.1111/j.1365-3156.2012.03089.x 22994151

19. Kranzer K, Govindasamy D, Ford N, Johnston V, Lawn SD. Quantifying and addressing losses along the continuum of care for people living with HIV infection in sub-Saharan Africa: a systematic review. J Int AIDS Soc. 2012;15(2):17383. doi: 10.7448/IAS.15.2.17383 23199799

20. Bor J, Fox MP, Rosen S, Venkataramani A, Tanser F, Pillay D, et al. Treatment eligibility and retention in clinical HIV care: A regression discontinuity study in South Africa. PLoS Med. 2017;14(11):e1002463. doi: 10.1371/journal.pmed.1002463 29182641

21. IeDEA. The International Epidemiology Databases to Evaluate AIDS (IeDEA) [cited 2016 Dec 2]. Available from: http://iedea.org/.

22. Fritz CQ, Blevins M, Lindegren ML, Wools-Kaloutsian K, Musick BS, Cornell M, et al. Comprehensiveness of HIV care provided at global HIV treatment sites in the IeDEA consortium: 2009 and 2014. J Int AIDS Soc. 2017;20(1):20933. doi: 10.7448/IAS.20.1.20933 28364561

23. Duda SN, Farr AM, Lindegren ML, Blevins M, Wester CW, Wools-Kaloustian K, et al. Characteristics and comprehensiveness of adult HIV care and treatment programmes in Asia-Pacific, sub-Saharan Africa and the Americas: results of a site assessment conducted by the International epidemiologic Databases to Evaluate AIDS (IeDEA) Collaboration. J Int AIDS Soc. 2014;17(1):19045. doi: 10.7448/IAS.17.1.19045 25516092

24. Joint United Nations Programme on HIV/AIDS. UNAIDS Database of National HIV Guidelines [cited 2016 Dec 2]. Available from: http://www.who.int/hiv/pub/national_guidelines/en

25. IAPAC. Global HIV Policy Watch: International Association of Providers of AIDS Care; [cited 2016 Dec 2]. Available from: http://www.hivpolicywatch.org/.

26. Gupta S, Granich R. When will sub-Saharan Africa adopt HIV treatment for all? South Afr J HIV Med. 2016;17(1):1–6.

27. Gupta S, Williams B, Montaner J. Realizing the potential of treatment as prevention: global ART policy and treatment coverage. Curr HIV/AIDS Rep. 2014;11(4):479–86. doi: 10.1007/s11904-014-0230-z 25266850

28. Ying R, Granich RM, Gupta S, Williams BG. CD4 Cell Count: Declining Value for Antiretroviral Therapy Eligibility. Clin Infect Dis. 2016;62(8):1022–8. doi: 10.1093/cid/civ1224 26826372

29. Joint United Nations Programme on HIV/AIDS. Global AIDS Update 2016. Geneva: Joint United Nations Programme on HIV/AIDS; 2016

30. World Health Organization. Rapid advice: antiretroviral therapy for HIV infection in adults and adolescents. Geneva: World Health Organization: 2009.

31. World Health Organization. Consolidated Guidelines on the use of Antiretroviral Drugs for Treating and Preventing HIV Infection: Recommendations for a Public Health Approach. Geneva: World Health Organization; 2013.

32. Ford N, Calmy A, Hurst S. When to start antiretroviral therapy in resource-limited settings: a human rights analysis. BMC Int Health Hum Rights. 2010 Mar 31;10:6. doi: 10.1186/1472-698X-10-6 20356356

33. Kluberg SA, Fox MP, LaValley M, Barnighausen T, Pillay D, Bor J. Do ART Eligibility Expansions Crowd Out the Sickest? Evidence From South Africa. Conference on Retroviruses and Opportunistic Infections; 2016 Feb 22–25; Boston, MA, USA.

34. Plazy M, Dabis F, Naidu K, Orne-Gliemann J, Barnighausen T, Dray-Spira R. Change of treatment guidelines and evolution of ART initiation in rural South Africa: data of a large HIV care and treatment programme. BMC Infect Dis. 2015;15:452. doi: 10.1186/s12879-015-1207-2 26497054

35. Lahuerta M, Ue F, Hoffman S, Elul B, Kulkarni SG, Wu Y, et al. The Problem of Late ART initiation in Sub-Saharan Africa: A Transient Aspect of Scale-up or a Long-term Phenomenon? J Health Care Poor Underserved. 2013;24(1):359–83. doi: 10.1353/hpu.2013.0014 23377739

36. Lessells RJ, Mutevedzi PC, Cooke GS, Newell M-L. Retention in HIV care for individuals not yet eligible for antiretroviral therapy: rural KwaZulu-Natal, South Africa. J Acquir Immune Defic Syndr. 2011;56(3):e79–e86. doi: 10.1097/QAI.0b013e3182075ae2 21157360

37. Kranzer K, Bradley J, Musaazi J, Nyathi M, Gunguwo H, Ndebele W, et al. Loss to follow-up among children and adolescents growing up with HIV infection: age really matters. J Int AIDS Soc. 2017;20(1):21737. doi: 10.7448/IAS.20.1.21737 28715158

38. Wong VJ, Murray KR, Phelps BR, Vermund SH, McCarraher DR. Adolescents, young people, and the 90-90-90 goals: a call to improve HIV testing and linkage to treatment. AIDS. 2017;31 Suppl 3:S191–s4. doi: 10.1097/QAD.0000000000001539 28665876

39. Joint United Nations Programme on HIV/AIDS. Young People and HIV. Geneva: Joint United Nations Programme on HIV/AIDS; 2012.

40. Mberi MN, Kuonza LR, Dube NM, Nattey C, Manda S, Summers R. Determinants of loss to follow-up in patients on antiretroviral treatment, South Africa, 2004–2012: a cohort study. BMC Health Serv Res. 2015;15:259. doi: 10.1186/s12913-015-0912-2 26141729

41. Van Cutsem G, Ford N, Hildebrand K, Goemaere E, Mathee S, Abrahams M, et al. Correcting for Mortality Among Patients Lost to Follow Up on Antiretroviral Therapy in South Africa: A Cohort Analysis. PLoS ONE. 2011;6(2):e14684. doi: 10.1371/journal.pone.0014684 21379378

42. Ford N, Migone C, Calmy A, Kerschberger B, Kanters S, Nsanzimana S, et al. Benefits and risks of rapid initiation of antiretroviral therapy: a systematic review and meta-analysis. AIDS. 2017; 32(1):17. doi: 10.1097/QAD.0000000000001671 29112073

43. Rosen S, Maskew M, Fox MP, Nyoni C, Mongwenyana C, Malete G, et al. Initiating Antiretroviral Therapy for HIV at a Patient's First Clinic Visit: The RapIT Randomized Controlled Trial. PLoS Med. 2016;13(5):e1002015. doi: 10.1371/journal.pmed.1002015 27163694. Erratum in: PLoS Med. 2016 Jun;13(6):e1002050.

44. Kay ES, Batey DS, Mugavero MJ. The HIV treatment cascade and care continuum: updates, goals, and recommendations for the future. AIDS Res Ther. 2016;13:35. doi: 10.1186/s12981-016-0120-0 27826353

45. Bor J, Ahmed S, Fox MP, Rosen S, Meyer-Rath G, Katz IT, et al. Effect of eliminating CD4-count thresholds on HIV treatment initiation in South Africa: An empirical modeling study. PLoS ONE. 2017;12(6):e0178249. doi: 10.1371/journal.pone.0178249 28617805

46. Hayes R, Floyd S, Schaap A, Shanaube K, Bock P, Sabapathy K, et al. A universal testing and treatment intervention to improve HIV control: One-year results from intervention communities in Zambia in the HPTN 071 (PopART) cluster-randomised trial. PLoS Med. 2017;14(5):e1002292. doi: 10.1371/journal.pmed.1002292 28464041

47. Desai MA, Okal DO, Rose CE, Ndivo R, Oyaro B, Otieno FO, et al. Effect of point-of-care CD4 cell count results on linkage to care and antiretroviral initiation during a home-based HIV testing campaign: a non-blinded, cluster-randomised trial. Lancet HIV. 2017;4(9):e393–e401. doi: 10.1016/S2352-3018(17)30091-7 28579225

48. Granich RM, Gilks CF, Dye C, De Cock KM, Williams BG. Universal voluntary HIV testing with immediate antiretroviral therapy as a strategy for elimination of HIV transmission: a mathematical model. Lancet. 2009;373(9657):48–57. doi: 10.1016/S0140-6736(08)61697-9 19038438

49. Ford N, Nsanzimana S. Accelerating initiation of antiretroviral therapy. Lancet HIV. 3(11):e504–e5. doi: 10.1016/S2352-3018(16)30152-7 27658872

50. Amanyire G, Semitala FC, Namusobya J, Katuramu R, Kampiire L, Wallenta J, et al. Effects of a multicomponent intervention to streamline initiation of antiretroviral therapy in Africa: a stepped-wedge cluster-randomised trial. Lancet HIV. 2016;3(11):e539–e48. doi: 10.1016/S2352-3018(16)30090-X 27658873